Quarterly ResultJun 25, 2026, 06:07 AM
Addex Therapeutics Q1 Net Loss Widens to CHF 1.71M; Going Concern Risk
AI Summary
Addex Therapeutics reported an increased net loss of CHF 1.71 million for Q1 2026, compared to CHF 1.47 million in Q1 2025. The company's cash and cash equivalents significantly decreased to CHF 0.94 million as of March 31, 2026, from CHF 1.64 million at the end of 2025, raising substantial doubt about its ability to continue as a going concern beyond July 2026. Operationally, its spin-out Neurosterix is advancing a Phase 1 study for NTX-253, and Addex continues preclinical development for its GABAB PAM chronic cough candidate.
Key Highlights
- Net loss increased to CHF 1.71 million in Q1 2026 from CHF 1.47 million in Q1 2025.
- Operating loss decreased to CHF 0.48 million in Q1 2026 from CHF 0.61 million in Q1 2025.
- R&D expenses decreased to CHF 0.04 million in Q1 2026 from CHF 0.16 million in Q1 2025.
- G&A expenses decreased to CHF 0.45 million in Q1 2026 from CHF 0.52 million in Q1 2025.
- Share of net loss of associates increased to CHF 1.23 million in Q1 2026 from CHF 0.85 million in Q1 2025.
- Cash and cash equivalents were CHF 0.94 million as of March 31, 2026, down from CHF 1.64 million at Dec 31, 2025.
- Neurosterix (20% equity interest) is progressing Phase 1 study for NTX-253, expected to complete in July.
- Company faces material uncertainty regarding going concern, with cash sufficient only through July 2026.
Price Impact
More from ADXN